Innocan Pharma Corporation (OTCMKTS:INNPF) (CSE:INNO) Stock Continues to Consolidate After Fall

0

Innocan Pharma Corporation (OTCMKTS:INNPF) (CSE:INNO) shares are trading in a narrow range. The stock has lost 24% over the past month.

Commercial data

On Friday, INNO stock rose 37.50% to C$0.77 with more than 55 shares, compared to its average volume of 102,000 shares.

Innocan Pharma publishes an important update on its LPT platform project

Innocan Pharma Corporation (OTCMKTS:INNPF) (CSE:INNO) has provided an important update regarding its research into CBD-loaded liposomes using Innocan’s LPT platform. The objective of this research is to provide a technology that combines the advantages of two well-known drugs and a delivery system to create a new drug product that can be used to treat a wide range of health problems therapeutically such as pain, multiple sclerosis, rheumatoid arthritis epilepsy and many other diseases.

The problem with CBD is that it breaks down quickly in the body and has low and variable oral bioavailability. Thus, it reduces any therapeutic effect. Innocan seeks to deliver CBD encapsulated in liposomes (the LPT platform), in order to build significant and long-lasting levels of CBD in the body. It is believed to create a much more effective and continuous therapeutic effect.

The first results of the experiments of its LPT platform on animals, in 2021, showed positive results. The latest study showed that CBD encapsulated in liposomes can be detected in sufficient quantities for up to 6 weeks after a single administration. Many more studies are expected to be conducted in 2022, which will shed more light on this question.

Innocan Israel has also entered into a research and licensing agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem, for the design, preparation, characterization and evaluation of liposomes loaded with CBD (or other cannabinoids ).

key quote

Iris Bincovich, CEO of Innocan Pharma, said: “We are excited about our ability to encapsulate CBD molecules in liposomes. The encapsulation process is a difficult task and we are satisfied with the first results. The ability to create sustained release of CBD, while maintaining therapeutic tissue/blood levels, may open LPT technology to uses in a wide variety of clinical indications.

technical data

INNO stock is trading above the 20-day and 200-day moving averages of $0.67 and $0.69 respectively. Moreover, the stock is below the 50-day moving average of $0.9.

Share.

Comments are closed.